This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Ascendis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Ascendis Pharma CEO'su Jan Mikkelsen, Dec2007 tarihinde atandı, in görev süresi 18.33 yıldır. şirketin hisselerinin 0.62% doğrudan sahiptir ve bu hisselerin değeri € 76.13M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.7 yıl ve 7.4 yıldır.

Anahtar bilgiler

Jan Mikkelsen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	18.3yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	9.7yrs
Yönetim Kurulu ortalama görev süresi	7.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jan Mikkelsen (65 yo)

18.3yrs

Görev süresi

Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Mikkelsen	President	18.3yrs	Veri yok	0.62% € 76.1m
Scott Smith	CFO, Executive VP & Member of Executive Board	9.7yrs	Veri yok	0.0041% € 497.3k
Pedersen Anni Lotte Sonderbjerg	Executive VP	18.3yrs	Veri yok	0.032% € 3.8m
Michael Jensen	Executive VP	12.8yrs	Veri yok	0% € 0
Mads Bodenhoff	Senior VP	2.2yrs	Veri yok	0.00031% € 37.9k
Chad Fugure	Vice President of Investor Relations	no data	Veri yok	Veri yok
Flemming Jensen	Executive Vice President of Product Supply & Quality	10.7yrs	Veri yok	0.032% € 3.8m
Kennett Sprogoe	Executive VP and Head of Research & Product Development	10.3yrs	Veri yok	0.032% € 3.9m
Stina Singel	Executive VP & Head of Clinical Development for Oncology	4.3yrs	Veri yok	Veri yok
Joseph Kelly	Head of U.S. Commercial of Endocrinology	3.9yrs	Veri yok	Veri yok
Sherrie Glass	Chief Business Officer	1.6yrs	Veri yok	0% € 0
Jay Wu	Executive VP & President of Ascendis US	1.3yrs	Veri yok	0.0017% € 211.4k

9.7yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: A71 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Mikkelsen	President	18.3yrs	Veri yok	0.62% € 76.1m
Albert Cha	Independent Chairman	11.4yrs	€139.72k	0.0060% € 738.0k
William Fairey	Independent Director	3.6yrs	€73.01k	0.0034% € 419.1k
Lisa Morrison	Independent Director	9yrs	€92.64k	0.0025% € 310.4k
Lars Holtug	Independent Director	7.4yrs	€96.17k	0.0069% € 838.2k
Siham Imani	Independent Director	3.6yrs	€69.48k	0.0037% € 458.2k
Jean-Jacques Bienaime	Non-Executive Director	less than a year	Veri yok	Veri yok

7.4yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: A71 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/23 17:58
Gün Sonu Hisse Fiyatı	2026/04/17 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Ascendis Pharma A/S 30 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Eliana Merle	Barclays
Tazeen Ahmad	BofA Global Research
Michelle Gilson	Canaccord Genuity

This company listing is no longer active

Ascendis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ascendis Pharma A/S Elects Jean-Jacques Bienaimé as New Non-Executive Member of the Board

Ascendis Pharma A/S, Annual General Meeting, Mar 23, 2026

Ascendis Pharma A/S, Annual General Meeting, May 27, 2025

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Recent updates

Ascendis Pharma A/S(NasdaqGS:ASND) dropped from NASDAQ Composite Index

Ascendis Pharma A/S Announces New Data from Ongoing Coach Trial Demonstrating Transcon hGH Accelerates Transcon CNP’S Benefits Beyond Linear Growth in Children with Achondroplasia

Ascendis Pharma A/S Launches YUVIWEL (Navepegritide) In The United States

Ascendis Pharma A/S Elects Jean-Jacques Bienaimé as New Non-Executive Member of the Board

Ascendis Pharma A/S Reports New Insights Trial Results For TransCon HGH In Turner Syndrome

Ascendis Pharma Announces Durable Benefits of Transcon Cnp in Children with Achondroplasia

Ascendis Pharma A/S Announces FDA Approves Once-Weekly YUVIWEL®? (Navepegritide) for Children with Achondroplasia Aged 2 Years and Older

Ascendis Pharma A/S, Annual General Meeting, Mar 23, 2026

Ascendis Pharma A/S to Report Fiscal Year 2025 Results on Feb 11, 2026

Ascendis Pharma A/S Announces Topline Results from Week 52 of COACH Trial Evaluating Combination Therapy in Children with Achondroplasia

Ascendis Pharma A/S Announces Results of Pivotal Approach Trial of Transcon CNP (Navepegritide) in Children with Achondroplasia Published in Jama Pediatrics

Ascendis Pharma A/S Announces New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon®? PTH (Palopegteriparatide)Treated Adults with Hypoparathyroidism

Ascendis Pharma A/S to Report Q3, 2025 Results on Nov 12, 2025

Ascendis Pharma A/S Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP

Ascendis Pharma A/S to Report Q2, 2025 Results on Aug 07, 2025

FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S Announces New Data from Week 156 of its Phase 3 PaTHway Trial Confirms Sustained Response to TransCon PTH Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data At Endo 2025

Ascendis Pharma A/S Announces Week 26 Interim Analysis Results from Its Ongoing Coach Trial

Ascendis Pharma A/S Announces Fda Acceptance of Transcon®? Cnp Nda for Priority Review

Ascendis Pharma A/S Announces New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (navepegritide)

Ascendis Pharma A/S Announces New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S, Annual General Meeting, May 27, 2025

Ascendis Pharma A/S to Report Q1, 2025 Results on May 01, 2025

Ascendis Pharma A/S Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma A/S (NasdaqGS:ASND) announces an Equity Buyback for $18.25 million worth of its shares.

Ascendis Pharma A/S to Report Fiscal Year 2024 Results on Feb 12, 2025

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Ascendis Pharma A/S Announces Positive Week 26 Topline Results from New Insights

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Accepts for Supplemental Biologics License Application for TransCon HGH for Adult GHD

Third quarter 2024 earnings released: €1.72 loss per share (vs €2.88 loss in 3Q 2023)

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: €1.91 loss per share (vs €2.16 loss in 2Q 2023)

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022)

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022)

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism